Published in Vaccine Weekly, August 11th, 1997
The team, including David D. Ho, Martin Markowitz, and John P. Moore of the Aaron Diamond AIDS Research Center (ADARC), studied HIV antibody responses to HIV-1 Env and Gag antigens in several cohorts of HIV infected individuals.
They found, in agreement with previous studies, that only long-term nonprogressors (LTNP) mount effective anti-gp120 antibody responses. In contrast, most people infected with HIV mount a massive, but almost completely ineffective response to the antigen.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly